# Clinical Trials Data EGFR - Document 111

# GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

## Clinical Trial: https://clinicaltrials.gov/study/NCT02047903

"eligibilityCriteria": "Inclusion criteria:\n\n\* EGFR- tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations\n\* Age \\>= 18 years\n\* No diagnostic or therapeutic measures beyond routine clinical practice are required\n\* Patients for whom the treating physician has decided to initiate treatment with GIOTRIF\n\* Written informed consent prior inclusion\n\nExclusion criteria:\n\n\* Contraindication for Afatinib according to the Summary of Product characteristics\n\* Participation in another clinical study until 30 days after end of treatment\n\* Prior systemic chemotherapy (Neo-/adjuvant therapy is permitted)\n\* Previous treatment with an EGFR-tyrosine kinase inhibitor\n\* Patients not willing or not able to fill in quality of life questionnaires\n\* Patients with missing or impaired legal capacity\n\* Pregnancy",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "NSCLC-EGFR mutation positive",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with an EGFR gene mutation would be eligible to participate, provided they meet all other inclusion criteria and none of the exclusion criteria apply to them. Specifically, the inclusion criteria mention that the study is open to "EGFR-tyrosine kinase inhibitor (TKI) naive patients with histologically confirmed locally advanced or metastatic NSCLC with activating EGFR-mutations," which indicates that patients with an EGFR mutation are indeed the target population for this study. However, the patient must also not have been previously treated with an EGFR-TKI, among other conditions specified in the exclusion criteria.